Skip to main content
. 2021 Feb 4;29(3-4):127–137. doi: 10.1038/s41434-021-00231-3

Fig. 2. Sciatic nerve conduction studies in Cx32 KO and age matched WT mice at 6 months post NT-3 gene transfer.

Fig. 2

In Cx32 KO mice, CMAPs were significantly improved with NT-3 gene therapy compared to the untreated (UT) controls. Compared to WT controls there was normalization of the CMAP amplitude while the UT group had 13% smaller CMAP amplitude than the WT mice (a). Error bars are ±SEM; n = 5 (WT), n = 14 (UT), n = 12 (NT-3), *p = 0.0307 (WT vs. UT), *p = 0.0103 (UT vs. NT-3), One-way ANOVA with Tukey’s multiple comparisons test. Representative waveforms of the sciatic nerve motor nerve conduction from WT, UT and NT-3 treated Cx32 KO are shown; base time for middle panel is 1 ms while others are 0.5 (b). The nerve conduction velocity (NCV) was also significantly improved with treatment corresponding to a 20.9% increase compared to UT cohort (c). NCV in the UT mice were 30.5% slower compared to WT whereas this slowing decreased to 16% in NT-3 treated mice. Error bars are ±SEM; n = 6 (WT), n = 14 (UT), n = 12 (NT-3), ****p < 0.0001 (WT vs UT), **p = 0.0016 (WT vs NT-3), ***p = 0.0003 (UT vs NT-3), One-way ANOVA with Tukey’s multiple comparisons test.